INTRODUCTION {#s1}
============

Presently, there are more than 400 hereditary cancer syndromes, accounting for 5%--10% of all cancers ([@COLBYMCS001230C22]; [@COLBYMCS001230C12]). There are 12 million individuals in the United States and 40 million in the world living with heritable cancer, generating a considerable burden of morbidity and mortality as well as substantial societal costs. The continued identification and characterization of cancer-predisposing genes has allowed for the establishment of more accurate risk assessment, predictive testing for family members, and gene-specific tailored clinical management, all of which can aid in early cancer detection or even prevention.

Lhermitte--Duclos disease (LDD), also known as dysplastic gangliocytoma of the cerebellum, is a hamartomatous lesion characterized by a slowly enlarging mass within the cerebellar cortex that results in global thickening of the cerebellar folia ([@COLBYMCS001230C27]). The presentation of LDD can mimic many common disorders including headache, epilepsy, and stroke. LDD is believed to be a pathognomonic feature of Cowden syndrome (CS), a multisystem autosomal dominant hereditary disorder characterized by multiple hamartomas and an elevated risk for benign and malignant neoplasms ([@COLBYMCS001230C20]; [@COLBYMCS001230C28]). Presently, the only known etiology for LDD is germline phosphatase and tensin homolog (*PTEN*) mutation ([@COLBYMCS001230C46]).

CS is estimated to affect 1 in 200,000 individuals ([@COLBYMCS001230C24]), although this is likely an underestimate considering the extensive degree of phenotypic variability observed in this disorder. Indeed, CS is a clinical mimic with individual features resembling normal variation or alternative disorders. Thus, it is difficult to recognize and hence, remains underdiagnosed. In such situations, having a molecular diagnostic would be desirable. The first identified CS susceptibility gene, *PTEN*, encodes a ubiquitously expressed dual specificity phosphatase that regulates critical cellular processes such as cell cycle, cell migration, and apoptosis ([@COLBYMCS001230C23]). Although the discovery of *PTEN* as a CS susceptibility gene laid the foundation for gene-enabled clinical management of *PTEN* mutation-positive patients ([@COLBYMCS001230C36]), this subset of patients accounts for only ∼25% of CS ([@COLBYMCS001230C35]). Relatedly, even with subsequent identification of germline alterations in *SDHB-D* ([@COLBYMCS001230C25]), *PIK3CA*/*AKT1* ([@COLBYMCS001230C29]), and *KLLN* ([@COLBYMCS001230C3]) in a subset of *PTEN* wild-type CS patients, ∼50% remain wild-type for all known CS predisposition genes.

Although adult-onset LDD has been believed to be pathognomonic for *PTEN* mutation, over the years, adults with LDD have been found not to have *PTEN* or pathway (*PIK3CA/AKT1*) alterations. Therefore, despite the rarity of this disease entity (estimated at 1 in 1,000,000), LDD provides a valuable patient population for discovery of other CS-relevant predisposition genes, which like *PTEN*, have far-reaching somatic implications in common sporadic neoplasias.

In this study, we utilized next-generation sequencing to analyze exomes of eight unrelated CS probands with LDD and who are wild-type for all known CS susceptibility genes. Variant prioritization revealed a pathogenic germline heterozygous variant in the receptor tyrosine kinase epidermal growth factor receptor (*EGFR* NM_005228: c.977G\>T, p.Cys326Phe) in one proband that disrupts a disulfide bridge in the extracellular domain of the receptor. We show the *EGFR* p.Cys326Phe variant is an activating mutation resulting in increased EGFR autophosphorylation, indicating enhanced receptor activation. We also observed increased downstream phosphorylation of ERK1/2 and AKT, consistent with pathway activation mimicking loss-of-function of PTEN ([@COLBYMCS001230C45]; [@COLBYMCS001230C9]; [@COLBYMCS001230C42], [@COLBYMCS001230C43],[@COLBYMCS001230C44]). Our findings suggest that activating mutations in *EGFR* contribute to the pathogenesis of *PTEN* wild-type LDD. Finding the underlying molecular etiology of identical phenotypes facilitates specific medical management and correct choice of targeted therapy or in the future, targeted prevention.

RESULTS {#s2}
=======

Clinical Presentation and Family History {#s2a}
----------------------------------------

We discuss a 43-yr-old female patient who presented to the emergency department at age 41 with left arm weakness and slurred speech. Investigation of the underlying cause of the presentation resulted in the incidental finding of a 5.0-cm mass within the right cerebellar hemisphere on a computed tomography (CT) brain scan without contrast. The mass was predominantly low density and demonstrated some mass effect on the fourth ventricle. The mass was further characterized using magnetic resonance imaging (MRI) with and without contrast, which revealed a striated appearance and thickening of the cerebellar folia, both characteristic of Lhermitte--Duclos disease. The MRI also revealed a focus of restricted diffusion in the right parietal convexity consistent with an area of acute infarction in the distribution of the right middle cerebral artery, which was believed to be the etiology for the patient\'s chief complaint. The patient was referred to our institution for clinical and genetic workup relevant to CS, because LDD is a pathognomic feature of the disease. She was found to have macrocephaly (occipital frontal circumference of 58.5 cm) but tested negative for germline alterations in genes known to be associated with CS (*PTEN, SDHB-D, PIK3CA/AKT1, KLLN*).

Family pedigree was notable for overrepresentation of colorectal cancer from the paternal side, as well as the existence of autism spectrum disorder (both CS-related features) in the 14-yr-old daughter of the proband (Supplemental Fig. S1). Unfortunately, no genomic DNA could be obtained from other family members for mutation testing, so we proceeded by whole-exome sequencing (WES) of germline genomic DNA from our patient and seven other unrelated CS probands, also diagnosed with LDD and wild-type for all known CS susceptibility genes ([Fig. 1](#COLBYMCS001230F1){ref-type="fig"}). The median age at diagnosis of LDD was 35 (range 9--44 yr). The majority of patients presented with other clinical manifestations of CS in addition to the LDD diagnosis (Supplemental Table S2).

![Experimental design for candidate gene prioritization and functional analysis. The pilot series of eight was selected from a larger pool of Lhermitte--Duclos disease (LDD) patients shown to be wild-type for *PTEN, SDHB-D*, *AKT1*, and *PIK3CA* variants/mutations and *KLLN* hypermethylation. CS/CSL, Cowden syndrome/CS-like; WES, whole-exome sequencing; CNVs, copy-number variants; ACMG, American College of Medical Genetics and Genomics.](ColbyMCS001230_F1){#COLBYMCS001230F1}

Genomic Analyses {#s2b}
----------------

Filtration of variants using the ANNOVAR ([@COLBYMCS001230C41]) variants reduction pipeline (<http://www.openbioinformatics.org/annovar/>) resulted in a prioritized gene variant count ranging 43--127 for each patient. As expected, we found no germline variants in the known CS susceptibility genes in the patient exomes, thus validating our initial mutation scanning results. We also analyzed our exomes for germline mutations in cancer-associated genes according to the American College of Medical Genetics and Genomics (ACMG) guidelines ([@COLBYMCS001230C14]) and other genes known to be associated with hereditary cancer syndromes with clinical phenotypic overlap with Cowden syndrome. This analysis also included exon-level copy-number variant (CNV) analysis using the eXome-Hidden Markov Model (XHMM) algorithm ([@COLBYMCS001230C10]). Interestingly, we found no germline mutations or CNVs in these genes within the studied exomes. Accordingly, and because LDD is a highly specific feature of CS, we first looked for variants in genes that are mutated in two or more patients. We found that only two of the eight patients shared germline missense heterozygous variants in TITIN (*TTN*), the largest gene in the human genome that has not been implicated in a protumorigenic overgrowth phenotype. Because *PTEN* is the only known susceptibility gene in LDD, we then hypothesized that LDD patients may be harboring germline variants in genes belonging to the PTEN signaling pathway. Indeed, we observed four missense heterozygous variants in genes that are upstream of or downstream from PTEN ([Table 1](#COLBYMCS001230TB1){ref-type="table"}). Among the four variants, only the epidermal growth factor receptor (*EGFR*) variant (NM_005228: c.977G\>T, p.Cys326Phe) has never been reported in known public databases (dbSNP138, 1000 Genomes, NHLBI-ESP6500, and ExAC). We then examined in silico the predicted functional impact and consistently noted a higher index of pathogenicity for the *EGFR* variant ([Tables 2](#COLBYMCS001230TB2){ref-type="table"} and [3](#COLBYMCS001230TB3){ref-type="table"}). Further structural modeling predicted that the *EGFR* p.Cys326Phe variant has a severe impact on protein structure because of breakage of a disulfide bond in the extracellular receptor domain and replacement of a 100% conserved cysteine with a phenylalanine residue ([Fig. 2](#COLBYMCS001230F2){ref-type="fig"}A,B). The *EGFR* p.Cys326Phe variant occurred in proband 5436-LDD7 ([Fig. 1](#COLBYMCS001230F1){ref-type="fig"}) and we found no other *EGFR* mutations in the seven unrelated LDD probands. Moreover, this variant was absent from germline genomic DNA of 28 LDD patients with known germline pathogenic *PTEN* mutations. Finally, exome sequencing and in silico exon-level CNV analysis of 60 unrelated *PTEN* wild-type patients with CS or Bannayan--Riley--Ruvalcaba syndrome (a hamartomatous overgrowth syndrome allelic to CS) without LDD did not reveal other *EGFR* mutations or copy-number alterations.

![*EGFR* p.Cys326Phe mutation is conserved and disrupts an extracellular disulfide bridge. (*A*) A sequence chromatogram of the *EGFR* codon affected by the nucleotide mutation and conservation of the C326 amino acid across multiple species. (*B*) The protein structure of EGFR, with an enlarged view of the cysteine residue at position 326 forming the Cys311--Cys326 disulfide bond in wild-type EGFR and the phenylalanine residue and disruption of the same disulfide bond in mutant EGFR. Structural modeling was performed using Swiss-PdbViewer (<http://spdbv.vital-it.ch>) and EGFR PDB structure 3NJP.](ColbyMCS001230_F2){#COLBYMCS001230F2}

###### 

Characteristics of four variants identified within the PTEN signaling pathway

  Gene      Chromosome    HGVS DNA Reference   HGVS protein reference   Variant type   dbSNP ID      Genotype
  --------- ------------- -------------------- ------------------------ -------------- ------------- --------------
  *EGFR*    7:55223610    NM_005228            p.Cys326Phe              Substitution   ---           Heterozygous
  *INSRR*   1:156823922   NM_014215            p.Arg87Cys               Substitution   rs374390533   Heterozygous
  *ILK*     11:6629361    NM_001014795         p.Arg59Trp               Substitution   ---           Heterozygous
  *MET*     7:116339877   NM_001127500         p.Ile247Val              Substitution   ---           Heterozygous

PTEN, phosphatase and tensin homolog; HGVS, Human Genome Variation Society; dbSNP, Database for Short Genetic Variations.

###### 

Prioritization of the PTEN signaling pathway candidate genes identified from eight unrelated LDD patients

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                   Gene                                                                                                                                                                                                   
  ---------------- --------------------------------------------------------------------- --------------------------------------------------------------- ---------------------------------------------------------------- -------------------------------------------------------------------------------------------------
  1000 Genomes     0                                                                     2/5008 (0.0004)\                                                0                                                                0
                                                                                         rs374390533                                                                                                                      

  NHLBI-ESP6500    0                                                                     2/13006 (0.0002)                                                0                                                                0

  ExAC             0                                                                     64/120676 (0.0005)                                              2/121380 (1.648e-05)                                             5/120756 (4.141e-05)

  MutationTaster   Disease-causing                                                       Disease-causing                                                 Disease-causing                                                  Disease-causing

  MutPred          Probability of deleterious mutation: 0.895                            Probability of deleterious mutation: 0.798                      Probability of deleterious mutation: 0.665                       Probability of deleterious mutation: 0.657

  Condel           Disease-causing                                                       Neutral                                                         Neutral                                                          Neutral

  Project HOPE     Loss of cysteine bridge → severe effect on 3D structure of protein\   Disturbance of salt bridge made by original wild-type residue   Disturbance of salt bridge made by original wild-type residue\   Homologous proteins exist with mutant residue at this position → mutation possibly not damaging
                   Mutation of 100% conserved residue                                                                                                    Wild-type residue not conserved at this position                 
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PTEN, phosphatase and tensin homolog; LDD, Lhermitte--Duclos disease; NHLBI, National Heart, Lung, and Blood Institute; ExAC, Exome Aggregration Consortium; Condel, Consensus Deleteriousness.

###### 

Sequencing parameters for the exome-sequenced patient 5436-LDD7

  Exome mean coverage   Bases covered ≥10 reads (%)   Targeted regions without reads (%)   Coverage at *EGFR* reported variant
  --------------------- ----------------------------- ------------------------------------ -------------------------------------
  195.9×                94.9                          0.25                                 154× (50% mutated allele)

Functional Analyses {#s2c}
-------------------

To investigate the in vitro impact of the *EGFR* p.Cys326Phe variant, we transiently transfected HEK293T cells with empty vector, wild-type, and p.Cys326Phe *EGFR* plasmids. Consistent with in silico predictions, immunoblotting of proteins downstream from EGFR demonstrated significantly increased phosphorylation of ERK1/2 and a slight increase of AKT phosphorylation at serine residue 473 in mutant cells relative to empty vector and *EGFR* wild-type cells ([Fig. 3](#COLBYMCS001230F3){ref-type="fig"}A). Furthermore, we also observed increased phosphorylation of EGFR at its autophosphorylation tyrosine sites Y992, Y1045, and Y1068, providing further evidence supporting enhanced mutant receptor activation ([Fig. 3](#COLBYMCS001230F3){ref-type="fig"}B). In support of our biochemical data, fluorescent visualization of green fluorescent protein (GFP)-tagged EGFR in transiently transfected HEK293T cells revealed pronounced clustering of EGFR in 293T-*EGFR-*C326F mutant cells relative to wild-type ([Fig. 3](#COLBYMCS001230F3){ref-type="fig"}C). Finally, we observed notable hypertrophy of 293T-*EGFR-*C326F mutant cells, a hallmark feature consistent with the pathobiology of human LDD phenotype (Supplemental Fig. S2).

![Functional analysis of *EGFR* p.Cys326Phe mutation. (*A*) A western blot assessing phospho-AKT, total AKT, phospho-ERK1/2, and total ERK1/2 expression in transiently transfected HEK293T cells. The quantitation bar plot appears below the western blot, with expression of phosphorylated proteins normalized to corresponding total protein. (*B*) A western blot assessing total EGFR, phospho-EGFR-Y992, phospho-EGFR-Y1045, and phospho-EGFR-Y1068 expression in transiently transfected HEK293T cells. The first two lanes represent commercially available cell lysates that serve as negative and positive controls of EGFR activation. The lysates are derived from A431 cells, known to have a large number of EGF binding sites, and representing an epidermal carcinoma of the vulva. The negative control (lane *1*) represents lysates extracted from overnight serum-starved A431 cells, hence signifying nonphosphorylated EGFR. The positive control (lane *2*) represents lysates extracted from A431 cells treated with 100 ng/mL EGF for 5 min, hence signifying active phosphorylated EGFR. Protein lysates from mutant cells (lane *4*) reveal notable EGFR phosphorylation compared with wild-type cells (lane *3*) even in the absence of EGF stimulation, reflecting constitutive receptor activation. (*C*) Confocal microscopy images of transiently transfected wild-type and p.Cys326Phe-mutant HEK293T cells, with the mutant cells demonstrating increased receptor clustering relative to wild-type cells (green). (*D*) The proposed model of the relationship between *PTEN* loss-of-function and *EGFR* gain-of-function mutations in Cowden syndrome (CS)-Lhermitte--Duclos disease (LDD). WT, wild-type.](ColbyMCS001230_F3){#COLBYMCS001230F3}

DISCUSSION {#s3}
==========

EGFR is a transmembrane growth factor receptor that plays a well-established role in carcinogenesis ([@COLBYMCS001230C40]). Raised awareness for *EGFR* mutations occurred with the discovery of a subset of non-small-cell lung cancers with specific activating somatic *EGFR* mutations that confer increased sensitivity to tyrosine kinase inhibitor therapy ([@COLBYMCS001230C18]; [@COLBYMCS001230C30]). Somatic *EGFR* mutations and amplifications occur in multiple cancer types ([@COLBYMCS001230C8]), whereas germline *EGFR* mutations are rare ([@COLBYMCS001230C7]) but most commonly occur in familial lung cancer ([@COLBYMCS001230C2]) and in a small subset of "never-smoking" lung cancer patients ([@COLBYMCS001230C30]; [@COLBYMCS001230C32]). Although the germline gain-of-function *EGFR* p.Cys326Phe mutation has not been previously reported, a somatic mutation at the same position (p.Cys326Arg) and with similar predicted gain-of-function effects is reported in The Cancer Genome Atlas (TCGA). Interestingly, this mutation was found in a renal cell carcinoma, a major CS-component cancer.

Knowing that *PTEN* is the only known LDD susceptibility gene and that LDD is highly pathognomonic of CS, our findings reveal that the *PTEN* wild-type subset of LDD patients indeed represents a genotypically heterogeneous population, especially when variable CS-overlapping clinical phenotypes are present (Supplemental Table S2). This may partly explain the absence of a shared genetic etiology among our pilot series of sequenced LDD patients. This is also confounded by the fact that LDD is rare and often reported as simplex cases---further complicated by the immense difficulty in obtaining cerebellar tissue for functional analyses. However, our data indicate that multiple genes within the PTEN signaling pathway may converge on and contribute to the same downstream signaling effects and, hence, disease etiology ([Table 1](#COLBYMCS001230TB1){ref-type="table"}). We show this biochemically for the *EGFR* p.Cys326Phe mutation, with increased activation of the ERK and AKT signaling pathways, mimicking loss-of-function *PTEN* mutations. Notably, although the proband does not have a family history of LDD, her pedigree shows an overrepresentation of colon cancer (Supplemental Fig. S1). Interestingly, *EGFR* germline mutations have never been reported in colon cancer and somatic mutations are rare ([@COLBYMCS001230C1]). Nonetheless, EGFR-targeted antibodies (cetuximab) have been FDA-approved for colon cancer treatment, chiefly because of the important role EGFR signaling plays in colon carcinogenesis.

Our observations here may be pertinent in the context that LDD is surgically difficult to completely resect. Thus, nonsurgical treatment is germane. Typically, a poly ADP ribose polymerase (PARP) inhibitor could be considered for germline *PTEN* mutation positive CS/CSL individuals and individuals with *PTEN*-related LDD. However, if an individual with LDD does not have the typical *PTEN* germline mutation but instead has a germline *EGFR* mutation, then some type of tyrosine kinase inhibitor (TKI) or antibody could be considered. TKIs have been utilized in a subset of lung cancers with somatic *EGFR* mutations with the majority of the latter occurring in the TK domain ([@COLBYMCS001230C18]; [@COLBYMCS001230C30]). Most of these TK domain mutations alter the structure of EGFR such that there is an increased binding affinity of the mutant receptor to the TKI instead of ATP ([@COLBYMCS001230C5]). Our LDD-*EGFR* mutation occurs in the extracellular cysteine-rich domain, where constitutive receptor dimerization and activation is predicted to occur. This should not yield the differential affinity of TKI to our mutant EGFR. Thus, in this situation, an antibody might be more appropriate. However, if indeed, as we show there is increased ERK signaling downstream from our *EGFR* mutant, then there is the theoretical possibility of using a mitogen-activated protein kinase (MAPK) inhibitor. Similarly, we also show a modest increase in phospho-AKT downstream from our constitutively activated mutant EGFR and perhaps an AKT inhibitor could also be considered.

The presence of a germline *EGFR* mutation in LDD, a cerebellar lesion, is particularly relevant because of the critical role EGFR plays in brain development ([@COLBYMCS001230C26]). Interestingly, somatic-activating *EGFR* mutations and loss-of-function *PTEN* mutations have both been highly associated with glioblastoma multiforme ([@COLBYMCS001230C34]). As an established oncogene, it is not surprising that a gain-of-function mutation will result in an overgrowth phenotype such as LDD. However, this is paralleled by the discovery of somatic-inactivating mutations of *LKB1* (also known as *STK11*, encoding serine/threonine kinase 11) in lung adenocarcinomas and squamous cell carcinomas ([@COLBYMCS001230C15]). Intriguingly, germline mutations in *LKB1* result in Peutz--Jeghers syndrome (considered in differential diagnosis for CS) characterized by intestinal hamartomas and increased lifetime cancer risk. Importantly, unlike somatic mutations in such cancer-relevant genes, heritable germline mutations result in elevated cancer lifetime risk across multiple generations. What remains elusive is whether our patient is at increased risk of other extracerebellar tumors known to be associated with *EGFR* aberrations, including head and neck, colon (given family history), or renal cell carcinoma as being associated with a similar mutation in TCGA. This indeed underscores the importance of pursuing genetic testing in individuals with relevant family history. Detection of pathogenic cancer-predisposing germline mutations not only prompts the initiation of gene-informed high-risk surveillance and/or preventive clinical measures but also includes the theoretical possibility of an *EGFR*-targeted therapy.

METHODS {#s4}
=======

Research Participants and Clinical Data {#s4a}
---------------------------------------

A total of 3399 individuals were accrued prospectively. These patients were recruited from both community and academic medical centers throughout North America, Europe (with \>85% originating from these two continents), and Asia using a standard protocol ([@COLBYMCS001230C36]). Eligible probands were CS-LDD patients who tested negative for germline alterations in *PTEN*, *SDHB*, *SDHC*, *SDHD*, *AKT1*, *PIK3CA,* and *KLLN* and met at least the relaxed International Cowden Consortium (ICC) operational diagnostic criteria (Supplemental Table S1). Scanning of genomic DNA for known gene candidate mutations was performed as we previously reported ([@COLBYMCS001230C25]), using a combination of denaturing gradient gel electrophoresis (*PTEN*), high-resolution melting curve analysis (*PTEN* and *SDHx*), and direct Sanger sequencing (all CS-known genes). Sanger sequencing of the *PTEN* promoter region was also performed, as we previously described ([@COLBYMCS001230C37]). Deletion analysis was performed for *PTEN* and *SDHx* using the multiplex ligation-dependent probe amplification (MLPA) assay, according to the manufacturer\'s protocol ([@COLBYMCS001230C33]). *KLLN* promoter methylation analysis was performed using the Sequenom MassArray assay, as previously reported ([@COLBYMCS001230C19]). For all selected individuals, we reviewed the Cleveland Clinic (CC) score ([@COLBYMCS001230C35]), a semiquantitative score that is based on weighting clinical features and that estimates the pretest probability of finding a germline *PTEN* mutation (<http://www.lerner.ccf.org/gmi/ccscore>). Given that all individuals are wild-type for *PTEN*, we used the CC score as a surrogate of phenotypic burden. We reviewed medical records, including pathology reports, for each research participant and extracted family history from clinical notes associated with cancer genetics and/or genetic-counseling visits, where applicable and with the individuals' consent. Cleveland Clinic Institutional Review Board approval (protocol \#8458) and written informed consents from all research participants were obtained for this study.

Exome Sequencing and Bioinformatic Analysis {#s4b}
-------------------------------------------

We subjected germline genomic DNA extracted from peripheral-blood leukocytes of the eligible probands to exome sequencing. Exome enrichment was performed with the TruSeq SBS v.3 Kit (Illumina), and subsequent 100-bp paired-end sequencing was performed with an Illumina HiSeq 2000 platform. Sequencing was performed at an Illumina Sequencing Service Center. Raw sequencing reads were mapped to the human reference haploid genome sequence (UCSC Genome Browser hg19) with the Burrows--Wheeler aligner ([@COLBYMCS001230C16]) (BWA v.0.6.1; <http://bio-bwa.sourceforge.net>). Insertion or deletion (indel) realignment, base- and quality-score recalibrations, and removal of polymerase chain reaction (PCR) duplicates from the resultant binary alignment map (BAM) files were performed with the Genome Analysis Toolkit ([@COLBYMCS001230C21]) (GATK; <http://www.broadinstitute.org/gatk/>), Sequence Alignment/Map ([@COLBYMCS001230C17]) (SAMtools), and Picard (<http://broadinstitute.github.io/picard/>). Variant discovery and genotype calling of single-nucleotide variants (SNVs) and short (\<50-bp) indels were performed with the GATK Haplotype Caller.

Variant Filtration and Annotation {#s4c}
---------------------------------

To prioritize causal variants, we applied ANNOVAR ([@COLBYMCS001230C41]) (<http://www.openbioinformatics.org/annovar/>). First, we discarded synonymous variants and intronic variants \>2 bp from exon boundaries. We retained variants in conserved genomic regions on the basis of a 46-species alignment and removed variants existing in segmental duplication regions. We excluded variants with a minor allele frequency (MAF) ≥ 0.0005 (or 0.05%) in the 1000 Genomes Project (August 2015 release) or the National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project (ESP) Exome Variant Server (ESP6500 data set) and variants reported in the Database for Short Genetic Variations (dbSNP)138 nonflagged database (excluding clinically associated single-nucleotide polymorphisms \[SNPs\]).

To predict the potential impact of missense variants on protein function, we used the program Consensus Deleteriousness ([@COLBYMCS001230C13]) (Condel v.1.5; <http://bg.upf.edu/fannsdb/>), which combines multiple prediction software algorithms (SIFT \[Sorting Intolerant from Tolerant\], PolyPhen-2 \[Polymorphism Phenotyping v2\], and MutationAssessor) into a single weighted score. We inspected all resultant variants through the Integrative Genomics Viewer ([@COLBYMCS001230C38]) (IGV; <https://www.broadinstitute.org/igv/home/>). We also used an in-house database containing variants from 11 individuals with sporadic polyposis and 13 exomes from individuals with unrelated phenotypes (connective-tissue disorders); these were sequenced with our cohort of research participants as an additional internal control filter. We excluded variants that appeared more than once in these in-house exome databases.

Copy-Number Variant Analysis {#s4d}
----------------------------

We implemented the XHMM algorithm to call CNVs from our exome-sequencing data, using default parameters. XHMM makes use of principal component analysis to normalize sequencing read depth and a hidden Markov model, while providing corresponding quality metrics for downstream prioritization ([@COLBYMCS001230C11]; [@COLBYMCS001230C31]). For the purposes of this study, we extracted data corresponding to cancer-associated genes according to the American College of Medical Genetics and Genomics (ACMG) guidelines ([@COLBYMCS001230C14]), and other genes known to be associated with hereditary cancer syndromes with clinical phenotypic overlap with Cowden syndrome. The mean per-target depth of coverage across all samples was 60. An XHMM quality score (SQ or Q_some) of 60 was used as a cutoff threshold for CNV filtration and prioritization.

Mutation Validation {#s4e}
-------------------

Mutations in candidate genes of interest were validated by PCR-based region-specific mutation analysis through Sanger sequencing. In brief, gene-specific primers encompassing exonic regions harboring the particular variations were designed (Supplemental Table S3). Sequencing was performed in the forward and reverse directions with Applied Biosystems ABI 3730xl DNA Analyzers at the Genomics Core of the Lerner Research Institute of the Cleveland Clinic and the Eurofins Genomics DNA-sequencing facility (Louisville). Primer sequences are listed in Supplemental Table S3. Resultant chromatograms were analyzed with Mutation Surveyor DNA Variant Analysis Software (SoftGenetics), and mutations were reported according to the Human Genome Variation Society (HGVS) guidelines. Incidental findings were reported to our genetic counselors to be communicated to the respective affected individuals and physicians of record according to the ACMG guidelines ([@COLBYMCS001230C14]).

Variant Interpretation and In Silico Pathogenicity Predictions {#s4f}
--------------------------------------------------------------

Variants retained after prioritization were considered potentially pathogenic. Further prioritization was performed through selection of shared genes with variants in multiple patients and variants belonging to genes in the *PTEN* signaling pathway. In silico assessment of the mutations' effects on protein integrity was performed through a combination of mutation-prediction algorithms, namely Condel (<http://bg.upf.edu/fannsdb/>), MutationTaster (<http://www.mutationtaster.org/>), and MutPred (<http://mutpred.mutdb.org/>).

Predicted Structural Effects of Variants {#s4g}
----------------------------------------

We predicted the structural effects of variants by using the HOPE server ([@COLBYMCS001230C39]), which integrates a series of standard algorithms to generate predictions. Structural information was obtained from the analysis of PDB structures 4KRP (EGFR), 4HI8 (ILK), 1IGR (INSRR), and 2UZX (MET). Annotations were obtained from UniProt entries EGFR_HUMAN, ILK_HUMAN, INSRR_HUMAN, and MET_HUMAN.

Cell Lines and Culture Conditions {#s4h}
---------------------------------

HEK293T cells (originally purchased from the American Type Culture Collection) in 2011 and obtained in 2014 from the Cleveland Clinic Lerner Research Institute Cell Culture Core were cultured in Dulbecco\'s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin and streptomycin. Cell lines were maintained at 37°C and 5% CO~2~ culture conditions and tested negative upon routine mycoplasma testing with the MycoAlert Mycoplasma Detection Kit (Lonza) at the C.E. lab (luminescence ratios \< 0.9). Cell lines used have not been listed as cells known to be misidentified according to the International Cell Line Authentication Committee ([@COLBYMCS001230C4]). Cell lines purchased from ATCC after 2010 have been authenticated by short-tandem-repeat PCR analysis.

Plasmids, Mutagenesis, and Cell-Line Transfection {#s4i}
-------------------------------------------------

We generated the *EGFR* p.Cys326Phe mutant plasmid via site-directed mutagenesis of GFP-tagged wild-type *EGFR* plasmid \#32751 ([@COLBYMCS001230C6]) (Addgene). Wild-type plasmids were mutagenized for the missense mutation of interest with the QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies). All expression constructs were validated by Sanger sequencing prior to transfection. For transient overexpression, cell lines were transfected with GFP-tagged *EGFR*^WT^, *EGFR*^C326F^, or empty vector plasmids using Lipofectamine 3000 reagent (Thermo Fisher) according to the manufacturer\'s instructions. Cells were grown for at least 24 h before harvesting or downstream analysis.

Immunoblotting {#s4j}
--------------

Protein was extracted from whole-cell lysates with the Mammalian Protein Extraction Reagent M-PER (Thermo Scientific Pierce) supplemented with a cocktail of protease and phosphatase inhibitors (Sigma-Aldrich) and was quantified with the BCA Protein Assay Kit (Thermo Scientific Pierce). Lysates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto nitrocellulose membranes. We performed immunoblotting using protein lysates extracted from HEK293T cells expressing empty vector, *EGFR* wild-type, and *EGFR* p.Cys326Phe plasmids. We blotted for anti-phospho-AKT S473 (Cell Signaling \#4060), anti-total AKT (Cell Signaling \#9272), anti-phospho-ERK1/2 (Cell Signaling \#9101), anti-ERK1/2 (Cell Signaling \#9102), and anti-GAPDH (Cell Signaling \#2118) antibodies, at the recommended dilutions. EGFR control cell extracts (Cell Signaling \#5634) were used as negative and positive controls of EGFR phosphorylation/activation. Blots were scanned digitally and quantified with the Odyssey Infrared Imaging System (Li-Cor Biosciences).

Immunofluorescence {#s4k}
------------------

Cells were seeded on coverslips and were fixed with 4% paraformaldehyde for 5 min at room temperature. Coverslips were mounted with ProLong Gold Antifade mountant with DAPI (Invitrogen). Slides were visualized and images were obtained with a TCS SP8 confocal microscope (Leica).

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

Exome-sequencing data has been deposited in the National Center for Biotechnology Information (NCBI) Sequence Read Archive (SRA) (<http://www.ncbi.nlm.nih.gov/sra/>) under accession number SRX1802645. The *EGFR* c.977G\>T, p.Cys326Phe mutation has been deposited to ClinVar (<http://www.ncbi.nlm.nih.gov/clinvar/>) under accession number SCV000299219.

Ethics Statement {#s5b}
----------------

Cleveland Clinic Institutional Review Board approval (protocol \#8458) and written informed consent from all research participants were obtained for this study.
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